Home

Nyxoah SA - Ordinary Shares (NYXH)

6.9900
+0.4900 (7.54%)
NASDAQ · Last Trade: Apr 4th, 3:17 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close6.500
Open6.680
Bid5.550
Ask7.700
Day's Range6.450 - 7.351
52 Week Range6.300 - 13.50
Volume291,658
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume90,745

Chart

About Nyxoah SA - Ordinary Shares (NYXH)

Nyxoah S.A. is a medical technology company focused on developing and commercializing innovative therapeutic solutions for the treatment of obstructive sleep apnea (OSA). Their primary product features a novel implantable neurostimulator designed to improve airway muscle function during sleep, thereby reducing the frequency of breathing disruptions caused by OSA. Nyxoah's approach offers a minimally invasive alternative to traditional continuous positive airway pressure (CPAP) therapy, aimed at enhancing patient comfort and compliance. The company is dedicated to advancing the understanding and treatment of sleep disorders, striving to improve the quality of life for patients worldwide. Read More

News & Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · April 3, 2025
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · March 26, 2025
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · March 26, 2025
FDA Issues Nyxoah an Approvable Letter for its Genio® System
By Nyxoah · Via GlobeNewswire · March 26, 2025
Earnings Scheduled For March 13, 2025benzinga.com
Via Benzinga · March 13, 2025
Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results
REGULATED INFORMATION
By Nyxoah · Via GlobeNewswire · March 13, 2025
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025
By Nyxoah · Via GlobeNewswire · March 10, 2025
Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
By Nyxoah · Via GlobeNewswire · March 3, 2025
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle EastFirst patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates
By Nyxoah · Via GlobeNewswire · February 19, 2025
Publication relating to transparency notifications
               
By Nyxoah · Via GlobeNewswire · January 20, 2025
Publication relating to transparency notifications
               
By Nyxoah · Via GlobeNewswire · December 20, 2024
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandFirst patients implanted with Genio at UCLH, London
By Nyxoah · Via GlobeNewswire · December 13, 2024
Information on the total number of voting rights and shares
REGULATED INFORMATION
By Nyxoah · Via GlobeNewswire · November 27, 2024
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference
By Nyxoah · Via GlobeNewswire · November 20, 2024
Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024
REGULATED INFORMATIONNovember 19, 2024, 7:00am CET / 1:00am ET
By Nyxoah · Via GlobeNewswire · November 19, 2024
Publication relating to transparency notifications
                
By Nyxoah · Via GlobeNewswire · November 18, 2024
Nyxoah Reports Third Quarter Financial and Operating Results
REGULATED INFORMATION
By Nyxoah · Via GlobeNewswire · November 6, 2024
Nyxoah Appoints John Landry as Chief Financial Officer
Nyxoah Appoints John Landry as Chief Financial Officer
By Nyxoah · Via GlobeNewswire · November 4, 2024
Publication relating to transparency notifications
              
By Nyxoah · Via GlobeNewswire · October 25, 2024
Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024
Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024
By Nyxoah · Via GlobeNewswire · October 22, 2024
Publication relating to transparency notifications
                
By Nyxoah · Via GlobeNewswire · October 15, 2024
Tesla, A. O. Smith And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 11, 2024
Information on the total number of voting rights and shares
REGULATED INFORMATION
By Nyxoah · Via GlobeNewswire · October 9, 2024
Publication relating to transparency notifications
                
By Nyxoah · Via GlobeNewswire · October 9, 2024
Nyxoah Raises $27 Million through its At-the-Market Offering
INSIDE INFORMATIONREGULATED INFORMATION
By Nyxoah · Via GlobeNewswire · October 7, 2024